Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
| ▸ | MC4R | P32245 | 2/20 | 0.53 |
| ▸ | MC3R | P41968 | 2/20 | 0.53 |
| ▸ | MC1R | Q01726 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474618 | 1.00 | ACE (0.60) | ACEALDH1A1SMN1; SMN2L3MBTL1ACE2 | |
| SCHEMBL28650436 | 0.98 | ACE (0.58) | ACEALDH1A1SMN1; SMN2L3MBTL1ACE2 | |
| SCHEMBL12798848 | 0.95 | ACE (0.55) | ACEALDH1A1SMN1; SMN2L3MBTL1ACE2 | |
| SCHEMBL6786426 | 0.94 | ACE (0.55) | ACEALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL3183657 | 0.94 | ACE (0.55) | ACEALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL3183667 | 0.94 | ACE (0.55) | ACEALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL6039762 | 0.94 | ACE (0.55) | ACEALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL5037359 | 0.91 | GYS1 (0.56) | ACEALDH1A1SMN1; SMN2ACE2CHRM2 | |
| SCHEMBL5037364 | 0.91 | GYS1 (0.56) | ACEALDH1A1SMN1; SMN2ACE2CHRM2 | |
| SCHEMBL3194380 | 0.91 | ACE (0.54) | ACEALDH1A1SMN1; SMN2ACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109321497-A | Long lysine bacillus ZJB-17009 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109321496-A | Citrobacter freundii ZJB-17010 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109321491-A | Xiangfang enterobacteria ZJB-17001 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109321494-A | Intermediate gram Lyu Wall bacterium ZJB-17004 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109321492-A | Leclercia adecarboxylata ZJB-17008 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109321490-A | Clostridium perfringen ZJB-17003 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109321493-A | The lysine of resistance to boron bacillus ZJB-17007 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109321495-A | Kluyvera cryocrescens ZJB-17005 and its application | 浙江工业大学 | 2019-02-12 | — | — | CN | claimed |
| CN-109182201-A | Enterobacter amnigenus I type ZJB-17002 of biology and its application | 浙江工业大学 | 2019-01-11 | — | — | CN | claimed |
| CN-109182200-A | Spindle lysine bacillus ZJB-17006 and its application | 浙江工业大学 | 2019-01-11 | — | — | CN | claimed |
| US-7629340-B2 | N-(6-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | claimed |
| US-7595398-B2 | N-(5-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | claimed |
| US-6531612-B2 | Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | claimed |
| US-20010008901-A1 | Nitrile derivatives that inhibit cathepsin K | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-19 | — | — | US | claimed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-0019411-B1 | 1-PHENYL-2-AMINOETHANOL DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-22 | — | — | EP | disclosed |
| US-4323575-A | TOPICAL ANTIINFLAMMATORY AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-04-06 | — | — | US | disclosed |
| EP-0019411-A1 | 1-Phenyl-2-aminoethanol derivatives, processes for their manufacture and pharmaceutical compositions thereof | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ACE 640/4885ALDH1A1 2400/4885SMN1; SMN2 4833/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | ACE 640/4885ALDH1A1 2400/4885SMN1; SMN2 4833/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ACE 640/4885ALDH1A1 2400/4885SMN1; SMN2 4833/4885 |
| US-20010008901-A1 | Nitrile derivatives that inhibit cathepsin K | CTSK, CTSH, CTSS | ACE 42/4885ALDH1A1 2193/4885SMN1; SMN2 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.